AI Terminal
NUFORMIX PLC
Pre-Annual General Meeting Information • Jul 31, 2023
4941_agm-r_2023-07-31_319b3042-c41a-4cb3-a919-49dad86cba34.html
Pre-Annual General Meeting Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 7165H
Nuformix PLC
31 July 2023
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Notice of Annual General Meeting ("AGM")
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the 2023 Notice of AGM has today been posted to its shareholders:
A full pdf version of the Notice of AGM will shortly be available for download from the Investor Information section on the Company's website www.nuformix.com.
The AGM will be held on 24 August 2023 at 10.00 am at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
| Nuformix plc | |
| Dr Dan Gooding, Executive Director | Via IFC Advisory |
| Stanford Capital Partners Limited | |
| Tom Price / Patrick Claridge (Corporate Finance) | +44 (0) 20 3650 3650 |
| John Howes / Bob Pountney (Corporate Broking) | +44 (0) 20 3650 3652 |
| IFC Advisory Limited | |
| Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 [email protected] |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOADFLBXXDLLBBD